In this study, four new tablet versions of two compounds will be investigated. The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood after doses of four different tablet versions. The tablet versions, participants will receive, i.e. the treatment arm participants will be assigned to, is decided by chance. Participants will receive one treatment for 10 days in the first period. For the second period, directly following, participants will receive a different treatment for five more days. The study can last for up to approximately 10 weeks for each participant. This includes a screening period (up to 3 weeks), two treatment periods (together a total of 15 days) and a follow-up visit (5 weeks after the last dosing)
1 Primary · 2 Secondary · Reporting Duration: From pre-dose PK sample (0 hours) at day 10 to PK sample 24 hours after dose administration
384 Total Participants · 2 Treatment Groups
Primary Treatment: Part A: Oral semaglutide · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Age 18 - 55 · Male Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: